- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02020499
Predictive Factors Study (TAPAS)
January 11, 2019 updated by: Ipsen
Non-interventional, Observational, Long Term Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel (ATG) Treatment in Patients With Acromegaly.
This is a long term study to evaluate common therapeutic algorithms and possible predictive parameters for Somatuline Autogel treatment in patients with Acromegaly.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
5
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- St Vincent's Hospital
-
St Leonards, New South Wales, Australia, 2065
- Royal North Shore Hospital
-
-
Queensland
-
Herston, Queensland, Australia, 4006
- Royal Brisbane & Women's Hospital
-
Woolloongabba, Queensland, Australia, 4102
- Princess Alexandra Hospital
-
-
Victoria
-
Fitzroy, Victoria, Australia, 3065
- St Vincent's Hospital
-
Heidelberg, Victoria, Australia, 3084
- The Austin Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adult subjects in hospitals and private practices, suffering from acromegaly who are scheduled to receive ATG or already on treatment with ATG for a maximum of 3 months.
Description
Inclusion Criteria:
- Diagnosis of Acromegaly.
- Males and females aged 18 years and older.
- Signed informed consent (patient must give consent to the collection of retrospective data).
- Patients who have had surgery may enter the study 3 months post-surgery and evaluated for the duration of the study.
- With the intention to be treated with ATG (decision to prescribe ATG made prior to inclusion into the study) or already being treated with ATG.
- If already being treated with ATG:
Previous ATG treatment maximum of 3 months. AND Minimum data available (demographic data, disease history including previous treatments, GH, IGF-1 levels at baseline and under treatment as applicable).
- Not receiving Dopamine Agonists or other medical therapy (Pegvisomant, or other somatostatin analogues) for the treatment or symptom control of acromegaly.
Exclusion Criteria:
- The subject has had radiotherapy in the last 5 years.
- The subject has had surgery in the last 3 months.
- The subject has already been included in this study.
- Participation in an interventional trial, or receiving experimental drug.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Acromegalic patients
Acromegalic subjects treated with Somatuline Autogel® (Lanreotide)
|
Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels from baseline
Time Frame: Baseline and 4 weeks
|
Baseline and 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels from baseline
Time Frame: Baseline, 1 year and 3 years
|
Baseline, 1 year and 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2014
Primary Completion (Actual)
September 1, 2015
Study Completion (Actual)
September 1, 2015
Study Registration Dates
First Submitted
December 19, 2013
First Submitted That Met QC Criteria
December 19, 2013
First Posted (Estimate)
December 25, 2013
Study Record Updates
Last Update Posted (Actual)
January 14, 2019
Last Update Submitted That Met QC Criteria
January 11, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A-9B-52030-265
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acromegaly
-
Andrea M. IsidoriCompletedAcromegaly CardiomyopathyItaly
-
Samsung Medical CenterNot yet recruitingAcromegaly Due to Pituitary AdenomaKorea, Republic of
-
Istituto Auxologico ItalianoPolitecnico di MilanoRecruiting
-
Camurus ABCompletedAcromegalyUnited States, Spain, United Kingdom, Germany, Russian Federation, Greece, Hungary, Italy, Poland, Turkey
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Completed
-
IpsenCompletedAcromegalyGermany, Netherlands, Sweden, Czechia, Denmark, France, Greece, Italy, Spain, United Kingdom
-
Novartis PharmaceuticalsCompletedAcromegalyItaly, Australia, Belgium, Germany, Switzerland, United States, France
-
Crinetics Pharmaceuticals Inc.CompletedAcromegalyUnited States, United Kingdom, Slovakia, Australia, Italy, Hungary, Brazil, Germany, Greece, New Zealand, Poland, Romania, Serbia
-
Chiasma, Inc.UnknownAcromegalyUnited States, Israel, Canada, Denmark, Netherlands, New Zealand, Australia, United Kingdom, Hungary, Italy, Poland, Bulgaria, Germany, Latvia, Slovenia, Sweden, Turkey
Clinical Trials on Somatuline Autogel® (lanreotide) 60, 90, 120 mg.
-
IpsenCompletedAcromegaly | Neuroendocrine TumoursSwitzerland, Austria, Germany
-
Universitaire Ziekenhuizen KU LeuvenIpsenCompletedPolycystic Liver DiseaseBelgium
-
Radboud University Medical CenterUnknown
-
IpsenCompletedMidgut Neuroendocrine Tumours | Pancreatic TumoursSpain, United Kingdom, Denmark, Belgium, Germany, France, Netherlands, Ireland, Italy, Poland
-
IpsenCompletedAcromegalyNetherlands, Germany, France, United Kingdom, Turkey, Belgium, Czechia, Finland, Italy
-
IpsenCompletedAcromegalyFrance, Brazil, Denmark, Finland, Greece, Korea, Republic of, Latvia, Netherlands, Norway, Poland, Romania, Russian Federation, Serbia, Sweden
-
Federico II UniversityUniversity of GenovaCompleted
-
Federico II UniversityOspedali dei ColliCompletedAdvanced Hepatocellular CarcinomaItaly
-
Universitaire Ziekenhuizen KU LeuvenIpsenCompleted
-
University of WashingtonCompletedPancreatectomy; Hyperglycemia | Pancreatic Fistula | Pancreaticoduodenal; Fistula | Pancreatic LeakUnited States